[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cosmetic-outcome\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cosmetic-outcome":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,43],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100471333","phase-3-a-randomized-trial-of-five-fraction-partial-breast-irradiation-rapid2-100471333",false,"NCT05417516","A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)","A Randomized Trial of Five-Fraction Partial Breast Irradiation (RAPID2)","Inclusion Criteria:\n\nFor inclusion in this study, patients must fulfill all of the following criteria:\n\n1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease (see AJCC TNM Cancer Staging, Appendix II).\n2. Treated by BCS with microscopically clear resection margins \\>= 1mm for invasive and non-invasive disease or no residual disease on re-excision.\n3. Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection or clinical assessment with a negative axillary ultrasound and\u002For biopsy, for women with unifocal tumours \\\u003C= 2cm, histologic grade 1 or 2, ER or PR+ and HER2-ve that are being planned for endocrine therapy\n\nExclusion Criteria:\n\nPatients who satisfy any of the following exclusion criteria are NOT eligible for this study:\n\n1. Age less than 50 years.\n2. Known to be BRCA 1 and\u002For BRCA 2 positive.\n3. Tumour size \\>3cm in greatest diameter on pathological examination.\n4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \\\u003C= 3cm remain eligible\n5. Evidence of a DCIS component \\> 3cm\n6. Lobular carcinoma only.\n7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible).\n8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible).\n9. History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma.\n10. Known pregnancy or currently lactating.\n11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma).\n12. Inability to plan the patient for the experimental technique.","FEMALE","50 Years","120 Years",{"count":20,"type":21},910,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The primary objective of this study is to determine in women with node negative BC ≤3cm in size, if PBI compared to WBI, both given once-a-day over 1 week following BCS, is non-inferior for LR and reduces adverse cosmesis. The primary outcomes are LR and patient-assessed cosmesis at 3 years post randomization.",[27,28,29],"Breast Neoplasm Female","Radiotherapy","Cosmetic Outcome","RECRUITING","2026-06-16",{"date":33,"type":34},"2026-06-18","ACTUAL",{"date":36,"type":34},"2023-11-20",{"date":38,"type":21},"2031-11",{"name":40,"class":41},"Ontario Clinical Oncology Group (OCOG)","OTHER",29,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100604017","tape-application-protocol-for-enhanced-scars-100604017","NCT07144046","Tape Application Protocol for Enhanced Scars","The Effect of Long-term Micropore Coverage on Cosmetic Outcomes After Mastectomy","TAPES","Inclusion Criteria:\n\n* Women undergoing mastectomi without primary recontruction\n* BMI between 18-5 and 35\n* Age between 18 and 80\n\nExclusion Criteria:\n\n* Known bandaid allergy\n* In need of Mepilex Border OP after surgery\n* Concurrent treatment with systemic steroid treatment or other immunosuppresants\n* Post surgical haematoma that requires surgical intervention\n* Known tendency to kelloid or hypertrophic scar formation","18 Years","80 Years",{"count":54,"type":21},90,[56],"NA","What is the purpose of this study? The Investigators want to find out whether applying Micropore surgical tape to the medial half of the mastectomy scar for 3 months helps improve its appearance after 12 months, compared to no intervention.\n\nWhy is this study important? Scars can cause discomfort and affect how people feel about their bodies. The tape is thought to reduce stress on healing skin and possibly lead to a better-looking scar. But The Investigators need strong evidence to know whether it really helps.\n\nHow will the study be done?\n\nThis is a randomized, observer-blinded trial.\n\nWomen having mastectomy are randomly assigned to either receive the tape on half their scar or receive no tape.\n\nA plastic surgeon and a breast surgeon-who do not know which side had tape-will evaluate wounds using photos after 3 and 12 months.\n\nPatients will also rate their scars using a questionnaire (POSAS), giving their personal view on color, thickness, stiffness, and symptoms like itch or pain.\n\nWhat else are The Investigators looking at?\n\nThe Investigators will examine whether the treated half of the scar looks better than the untreated half within the same woman-this helps control for individual skin differences.\n\nThe Investigators will also compare treated versus untreated areas across different women to see if there is a consistent benefit.\n\nIf the untaped half of scars looks different from control scars, this may suggest differences between the groups that affect results.\n\nWhat will this study reveal? It will show whether using the tape improves cosmetic outcomes after mastectomy, and whether patients and clinicians agree on how scars heal. The findings may guide better post-surgery care to reduce scars and improve confidence and quality of life.",[59,29],"Scar Improvement",[61,62,63,64,65],"Cosmetic Scar Evaluation","Long term wound dressing","Scar formation","Mastectomy","Breast Cancer","NOT_YET_RECRUITING","2025-08-20",{"date":69,"type":34},"2025-08-27",{"date":71,"type":21},"2025-09-01",{"date":73,"type":21},"2028-09-01",{"name":75,"class":41},"Herlev Hospital"]